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Abstract
Introduction: Of the more than one million global cases of breast cancer diagnosed each year, approximately
fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors.
Lack of effective therapies, younger age at onset, and early metastatic spread have contributed to the poor
prognoses and outcomes associated with these malignancies. Here, we investigate the ability of the histone
deacetylase inhibitor panobinostat (LBH589) to selectively target triple-negative breast cancer (TNBC) cell
proliferation and survival in vitro and tumorigenesis in vivo.
Methods: TNBC cell lines MDA-MB-157, MDA-MB-231, MDA-MB-468, and BT-549 were treated with nanomolar (nM)
quantities of panobinostat. Relevant histone acetylation was verified by flow cytometry and immunofluorescent
imaging. Assays for trypan blue viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
proliferation, and DNA fragmentation were used to evaluate overall cellular toxicity. Changes in cell cycle
progression were assessed with propidium iodide flow cytometry. Additionally, qPCR arrays were used to probe
MDA-MB-231 cells for panobinostat-induced changes in cancer biomarkers and signaling pathways. Orthotopic
MDA-MB-231 and BT-549 mouse xenograft models were used to assess the effects of panobinostat on
tumorigenesis. Lastly, flow cytometry, ELISA, and immunohistochemical staining were applied to detect changes in
cadherin-1, E-cadherin (CDH1) protein expression and the results paired with confocal microscopy in order to
examine changes in cell morphology.
Results: Panobinostat treatment increased histone acetylation, decreased cell proliferation and survival, and
blocked cell cycle progression at G2/M with a concurrent decrease in S phase in all TNBC cell lines. Treatment also
resulted in apoptosis induction at 24 hours in all lines except the MDA-MB-468 cell line. MDA-MB-231 and BT-549
tumor formation was significantly inhibited by panobinostat (10 mg/kg/day) in mice. Additionally, panobinostat up-
regulated CDH1 protein in vitro and in vivo and induced cell morphology changes in MDA-MB-231 cells consistent
with reversal of the mesenchymal phenotype.
Conclusions: This study revealed that panobinostat is overtly toxic to TNBC cells in vitro and decreases
tumorigenesis in vivo. Additionally, treatment up-regulated anti-proliferative, tumor suppressor, and epithelial
marker genes in MDA-MB-231 cells and initiated a partial reversal of the epithelial-to-mesenchymal transition. Our
results demonstrate a potential therapeutic role of panobinostat in targeting aggressive triple-negative breast
cancer cell types.




Department of Medicine, Section of Hematology and Medical Oncology,
Tulane University Health Sciences Center, 1430 Tulane Ave, New Orleans, LA
70112, USA
Tate et al. Breast Cancer Research 2012, 14:R79
http://breast-cancer-research.com/content/14/3/R79
© 2012 Tate et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Introduction
Over 200,000 new cases of invasive breast cancer are
diagnosed in the United States each year and approxi-
mately 40,000 of the patients diagnosed will die from
the disease [1]. Breast cancers are routinely classified by
stage, pathology, grade and expression of estrogen
receptor (ER), progesterone receptor (PR) or human epi-
dermal growth factor receptor (Her2/neu). Current suc-
cessful therapies include hormone-based agents that
directly target these receptors [2,3]. Triple-negative
breast cancer (TNBC) is a heterogeneous subset of neo-
plasms that is defined by the absence of these targets
[4-6]. Approximately 15% of globally diagnosed breast
cancers are designated as ER-, PR- and Her2/neu-nega-
tive [1,7,8]. Studies have shown that tumors of this
aggressive subtype are of higher histological grade, affect
a disproportionate number of young women, and are
more likely to recur earlier at distant sites, resulting in
poor overall prognoses [4,5,9,10]. To improve outcomes
of TNBC, we must unravel its biological pathways and
modes of progression and use that knowledge to
develop novel targets and therapies.
Histone deacetylase inhibitors (HDACis) have
emerged as a promising new class of multifunctional
anticancer agents [11,12]. That promise lies in the ability
of HDACis to effect multiple epigenetic changes in aber-
rant cells. In addition to regulating gene expression and
transcription through chromatin remodeling, HDACis
can also modulate a variety of cellular functions includ-
ing growth, differentiation, and survival [13,14] due, in
part, to their ability to enhance acetylation of a wide
range of proteins, including transcription factors, mole-
cular chaperones, and structural components [11,15,16].
Specifically, HDACis have been linked to several down-
stream effects in tumor cell lines which include: cell
cycle arrest, induction of apoptosis, inhibition of angio-
genesis, activation or inactivation of tumor suppressor
genes or oncogenes, and decreased invasion and metas-
tases [11,12,17].
Panobinostat (LBH589) is a potent pan-deacetylase
inhibitor that can block multiple cancer related path-
ways and reverse epigenetic events implicated in cancer
progression [18]. HDACs can be subdivided into two
groups: zinc-dependent (Class I, II, and IV) and zinc-
independent (Class III) [19]. Panobinostat is a potent
inhibitor with activity against Class I, II, and IV HDAC
enzymes, suggesting true pan-HDAC activity [18]. In
preclinical studies, panobinostat has shown potent inhi-
bitory activity at low nanomolar concentrations across a
wide range of hematologic malignancies including lym-
phoma, multiple myeloma and acute myeloid leukemia
[20-22]. It is also being investigated as a treatment
against non-responsive solid tumors as well as tumors
of the lung, thyroid, and prostate [23-26]. It has shown
synergy with chemotherapeutics, radiation, demethyla-
tors, proteasome inhibitors and other agents [27-29].
Based on these preclinical findings, panobinostat and
other HDACis have undergone a rapid phase of clinical
development with many entering clinical trials, both as
single agents or in combination with other therapies
[12,23,30,31]. To date, panobinostat has demonstrated
favorable clinical responses, with limited toxicity
[23,32,33]. There is a critical need to develop pleiotropic
therapies that specifically target the neoplasm as well as
the biological pathways and markers of TNBC progres-
sion. The purpose of this study was to determine the
ability of panobinostat to selectively target the TNBC
subtype of breast cancer cells, assessed by its effects on
the growth, survival, and tumorigenesis of a representa-
tive panel of TNBC cells. We also sought to characterize
the effects panobinostat on the regulation of breast can-
cer genes, related signaling pathways and morphology.
Materials and methods
Cell lines and reagents
Human TNBC (MDA-MB-157, MDA-MB-231, MDA-
MB-468, BT-549), MDA-MB-361 and HEK293T
(human embryonic kidney)) cell lines were obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA). MDA-MB-157, MDA-MB-231,
and BT-549 cells are characterized as triple-negative/
basal-B mammary carcinoma, while the MDA-MB-468
cells are characterized as triple-negative/basal-A mam-
mary carcinoma. MDA-MB-361 cells are characterized
as ER-positive/Progesterone receptor (PgR) negative,
luminal mammary carcinoma. Liquid nitrogen stocks
were made upon receipt and maintained until the start
of each study. MCF-7 cells, characterized as ER-positive/
PgR-positive luminal mammary carcinoma, were
obtained from frozen stocks routinely used in previous
experiments [34]. The ER-positive/PgR-positive ZR-75-1
human epithelial mammary ductal carcinoma cells were
a generous gift of Dr. Brian Rowan (Tulane University,
New Orleans, LA, USA). Cells were used for no more
than six months after being thawed with periodic
recording of morphology and doubling times to ensure
maintenance of phenotype. Cells were maintained at 37°,
5% CO2 in 10% (D)MEM (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum
(Hyclone, Salt Lake City, UT, USA) and 1% penicillin/
streptomycin (Invitrogen). Panobinostat was generously
provided by Novartis Pharmaceutical Inc. (East Hanover,
NJ, USA). Panobinostat was dissolved in dimethyl sulf-
oxide (DMSO) (Invitrogen) as a 1 mM stock solution
and kept at -20°C. The drug was diluted in culture
media and used at various concentrations as indicated.
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Histone acetylation
TNBC cells were plated at 70% confluency in 10% (D)
MEM and allowed to attach overnight. Cells were trea-
ted with panobinostat (100 nM, 200 nM) or vehicle for
18 hours, then fixed, permeabilized and stained with
acetyl-histone H3 (Lys9) antibody/Alexa Fluor® 488
Conjugate or acetyl-histone H4 (Lys8) antibody/Alexa
Fluor® 488 Conjugate (Cell Signaling Technology, Dan-
vers, MA, USA), followed by rhodamine phalloidin and
DAPI (4’,6-diamidino-2-phenylindole) counterstain
(Molecular Probes, Carlsbad, CA, USA) according to the
manufacturer’s instructions. Cells were dually analyzed
by BD LSR II flow cytometer and BD Pathway 855 bioi-
maging confocal system and images merged using BD
Attovision™ Software (BD Biosciences, San Jose, CA,
USA). Data are represented as mean fluorescence inten-
sity (mean ± SEM) of two independent experiments
with internal triplicates.
MTT cell proliferation assay
Proliferation was measured by MTT (3-(4, 5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
Cell Proliferation Assay, according to the manufacturer’s
protocol (ATCC). Briefly, cells were plated in 96-well
flat bottom plates at a density of 5 × 103 per 100 μl in
10% (D)MEM, allowed to attach overnight, and then
treated with panobinostat (50, 100, 200 nM) or vehicle
for 24 hours. MTT reagent (10 μl) was added to each
well (final concentration 0.5 mg/ml) and the plate incu-
bated at 37°C. After four hours, 100 μl of solubilization
solution (10% SDS) was added to each well and the
plate incubated for two hours. A matched control cell
standard curve using sequentially increased cell numbers
was included on the plate for each corresponding cell
line to determine growth inhibition. The absorbance
was read at 570 nm on a Synergy™ 4 Multi-Mode
Microplate Reader and analyzed with Gen5™ Data Ana-
lysis Software (BioTek, Winooski, VT, USA). Data are
represented as mean percent vehicle treated cell prolif-
eration ± SEM of triplicate experiments with internal
triplicates.
Trypan blue viability assay
Cells were plated in 96-well plates at a density of 5 ×
103 per 100 μl in 10% (D)MEM and allowed to adhere
overnight. Cells were treated with vehicle or panobino-
stat (50, 100, 200 nM) for 24 hours and harvested by
trypsinization. Cells were then stained with a trypan
blue solution (0.04% w/v, Invitrogen), and counted on a
Cellometer Vision automated cell counter (Nexcelom
Bioscience, Lawrence, MA, USA) according to the man-
ufacturer’s protocol. Cell viabilities are represented as
mean percent relative to matched, vehicle-treated cells ±
SEM of triplicate experiments with internal triplicates.
Apoptosis
Analysis of apoptosis was carried out using the Cell
Death Detection ELISAPLUS according to the manufac-
ture’s protocol (Roche Applied Science, Mannheim, Ger-
many). This quantitative DNA fragmentation
immunoassay uses monoclonal antibodies directed
against histone-complexed DNA. Briefly, cells (104 cells/
well) were plated in 96 well plates overnight and treated
for 24 hours with panobinostat (100, 200 nM) or vehicle
control. After cell lysis and centrifugation, the cell
lysates were tested for histone-complexed DNA frag-
ments. The absorbance was read at 405 nm on a
Synergy™ HT Multi-Mode Microplate Reader and ana-
lyzed with Gen5™ Data Analysis Software (Bio-Tek).
Apoptosis of the treated cells was expressed as mean
enrichment factor (treated cells over vehicle controls) ±
SEM of duplicate experiments with internal triplicates.
Cell cycle analysis
For cell cycle analysis, TNBC cells were plated overnight
in 10% (D)MEM and treated with 100 nM panobinostat
for 24 or 72 hours. Both floating cells and trypsinized
adherent cells were collected and combined for analysis.
Cells were fixed by dropwise addition into ice cold etha-
nol and stored at -20° overnight. Cells were then pel-
leted, washed, and stained for one hour with 50 μg/ml
propidium iodide in PBS containing 0.1 mg/ml ribonu-
clease A and 0.05% Triton X-100 (Sigma, St. Louis, MO,
USA). After gating to exclude debris, the DNA content
was measured using a LSR-II flow cytometer (BD Bios-
ciences). Data were analyzed with ModFit LT software
(Verity Software House, Topsham, ME, USA). Data are
represented as percent live cells of two independent
experiments.
Plasmid packaging and stable cell line generation
HEK293T cells were plated at 5.5 × 106 in a 10 cm dish
in 10 ml of 10% (D)MEM and allowed to adhere over-
night. The following day, the HEK293t cells were co-
transfected with the pLEmiR non-silencing turbo red
fluorescent protein (tRFP) vector construct (9 μg) and
the trans-lentiviral packaging mix and pLEX™ transfer
vector using the TransLenti Viral pLEX packaging sys-
tem, following the manufacturer’s instructions (Thermo
Scientific, Waltham, MA, USA). Virus was harvested 48
hours post-transfection and stored at -80°C. TNBC cell
lines were plated at 70% confluence in 10 cm dishes
with 10 ml of 10% (D)MEM and allowed to adhere over-
night. The following day, cells were transduced with
virus containing the pLEmiR tRFP vector (1:10 dilution)
in serum-free media following the manufacturer’s proto-
col. After four hours, the transduction media was
removed and replaced with 10% (D)MEM. After 24
hours, cells were treated with puromycin (Invitrogen) to
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select for vector expression. The resultant stable trans-
fectants were designated as MDA-MB-231-tRFP and
BT-549-tRFP.
Animal xenograft studies
Xenograft tumor studies were conducted as previously
described [34]. In short, CB-17/SCID female mice (four
to six weeks old) were obtained from Charles River
Laboratories (Wilmington, MA, USA). The animals were
allowed a period of adaptation in a sterile and patho-
gen-free environment with food and water ad libitum.
MDA-MB-231-tRFP and BT-549-tRFP cells were har-
vested in the exponential growth phase using a PBS/
ethylenediaminetetraacetic acid (EDTA) solution and
washed. Viable cells (5 × 106) in 50 μl of sterile PBS sus-
pension were mixed with 100 μl reduced growth factor
Matrigel (BD Biosciences) and injected bilaterally into
the inguinal mammary fat pad. On day three post cell
injection, mice were randomized into treatment groups
of five mice each: (vehicle control or 10 mg/kg panobi-
nostat). Beginning on day 14 post cell injection, animals
received intraperitoneal (i.p.) injections of the corre-
sponding drug treatment on a five-day on and two-day
off schedule for 28 days [18]. Tumor size was measured
with a digital caliper and calculated using the formula
4/3πLS2 (L = larger radius, S = smaller radius). At
necropsy, animals were euthanized by cervical disloca-
tion following CO2 exposure. Tumors, livers, lungs, and
brains were removed and snap frozen or fixed in 10%
formalin for future analysis. All procedures involving
animals were conducted in compliance with State and
Federal laws, the U.S. Department of Health and
Human Services, and guidelines established by Tulane
University Animal Care and Use Committee. The facil-
ities and laboratory animals programs of Tulane Univer-
sity are accredited by the Association for the
Assessment and Accreditation of Laboratory Animal
Care.
Human breast cancer quantitative reverse transcription
real-time PCR array
Human Breast Cancer and Estrogen Receptor Signaling
RT2 Profiler™ PCR Arrays (PAHS-005) were obtained
from SABiosciences (Frederick, MD, USA). MDA-MB-
231, MCF-7, and MDA-MB-468 cells were plated in
10% (D)MEM at 70% confluency and treated with 100
nM panobinostat or vehicle for 24 hours. Cells were
harvested by trypsinization and total RNA was isolated
using the RNeasy kit, according to the manufacturer’s
instructions (Qiagen, Valencia, CA, USA). The quantity
and quality of the RNA were determined by absorbance
at 260 and 280 nm using the NanoDrop ND-1000
(NanoDrop, Wilmington, DE, USA). Total RNA (1.5 μg)
was reverse-transcribed using the RT2 First Strand
cDNA synthesis kit, following the manufacturer’s proto-
col (SABiosciences) and then assayed via an optimized,
quantitative RT real-time PCR (qPCR) array to assess
panobinostat-associated changes in the expression of 84
genes related to breast cancer regulation and estrogen
receptor-dependent signal transduction, according to the
manufacturer’s protocol. Biological triplicates were run
for each sample.
CDH1 flow cytometry and immunofluorescent imaging
MDA-MB-231 cells were plated at 70% confluency in
10% (D)MEM and allowed to attach overnight. Cells
were then treated with panobinostat (100 nM) or vehicle
for 24 hours. Cells were harvested by gentle pipetting
(PBS with 5% fetal bovine serum), fixed, and stained
with Alexa Fluor® 488-conjugated CDH1 (E-cadherin)
antibody (BD Biosciences). The expression of CDH1
protein was determined by flow cytometry on a BD
LSRII instrument. Data are represented as mean percent
E-cadherin positive cells ± SEM of duplicate experi-
ments with internal triplicates. Paired cells were seeded
on BD Falcon 96-well black imaging plates. Staining is
represented by the following colors: Green = CDH1,
Red = phaloidin, Blue = DAPI nuclear stain. Confocal
immunofluorescent images were captured on the BD
Pathway 855 Bioimaging system and merged using BD
Attovision™ software (BD Biosciences).
ELISA for CDH1
MDA-MB-231 cells (105 cells/well) were plated over-
night in six-well plates and then treated for 24 hours
with panobinostat (100 nM) or vehicle control. Five
volumes of ice-cold lysis buffer (20 mM Tris-HCl, pH
7.5/150 mM NaCl/1 mM EDTA/1 mM ethylene glycol-
bis[b-aminoethyl ether]-N, N, N’, N’-tetraacetic acid
(EGTA)/1% Tween 20) supplemented with protease
inhibitor tablets (Roche Diagnostics, Indianapolis, IN,
USA) were added to each well. Cell lysates were
mechanically dissociated and centrifuged (10,000 × g for
15 minutes at 4°C), and then diluted 1:1 with calibrator
diluent. CDH1 levels were then determined by human
CDH1 ELISA according to the manufacturer’s instruc-
tions (R&D Systems, Minneapolis, MN, USA). The
absorbance was read at 450 nm on a Synergy™ HT
Multi-Mode Microplate Reader (Bio-Tek). Data are
represented as mean pg/ml of CDH1 ± SEM of dupli-
cate experiments with internal triplicates.
Immunohistochemical staining
Representative sections of tumor with adjacent tissues
were fixed in 10% neutral buffered formalin for 24 to 36
hours. Paraffin-embedded sections were prepared at 4
μm thickness followed by standard H & E staining.
Additional sections were manually deparaffinized in
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xylene, rehydrated in a series of graded ethanol solu-
tions, boiled in10 mM sodium citrate buffer (pH 6.0) for
ten minutes, then cooled for 20 minutes for antigen
retrieval. Sections were blocked for 30 minutes with
10% normal goat serum (Invitrogen), incubated over-
night in a 4° humidified chamber with rabbit anti-E-cad-
herin (Abcam, Cambridge, UK) at 1:30 dilution,
followed by one hour incubation with Alexa Fluor® 488
goat anti-rabbit secondary (Invitrogen). Fluorescent
images were captured on a Nikon TE2000 inverted
microscope with IPLab software (BD Biosciences, Rock-
ville, MD, USA).
Statistical analyses
Statistical analyses were carried out with GraphPad
Prism software (Graph-Pad Software, Inc., San Diego,
CA, USA). Studies involving more than two groups were
analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s post-hoc multiple comparison tests.
All others were subjected to unpaired Student’s t-test,
with P < 0.05 considered statistically significant.
Results
Panobinostat induces histone acetylation
To verify the effects of panobinostat as a relevant his-
tone deacetylase inhibitor, four TNBC cell lines, MDA-
MB157, MDA-MB-231, MDA-MB-468, and BT-549,
were treated with increasing concentrations of the drug
(100 to 200 nM) and assayed after 18 hours by flow
cytometry for antibodies to acetylated histones H3 and
H4. Panobinostat induced hyper-acetylation of histones
H3 (Lys9) and H4 (Lys8) in all four tested TNBC cell
lines, as seen in Figures 1A and 1B, respectively (***, P <
0.001). MDA-MB-468 cells were the least responsive to
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Figure 1 Panobinostat increases histone H3 (Lys9) and H4 (Lys8) acetylation in TNBC cell lines. Cells were treated with panobinostat (100,
200 nM) or vehicle (DMSO) for 18 hours, fixed, permeabilized and stained for acetyl-histones (A) H3 (Lys9) or (B) H4 (Lys8) and subjected to flow
cytometry. Data are presented as mean fluorescence intensity (mean ± SEM) of two independent experiments, (***, P < 0.001). (C-D) Confocal
images of TNBC cell lines treated with panobinostat (100 nM) or vehicle for 18 hours, fixed, permeabilized and stained red (rhodamine
phalloidin) for actin filaments and green (Alexa Fluor® 488) for acetyl-histones (C) H3 (Lys9) or (D) H4 (Lys8). Original magnification was 400×
with scale bars at 20 microns. DMSO, dimethyl sulfoxide; SEM, standard error of the mean; TNBC, triple-negative breast cancer.
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panobinostat with a 2.1-fold change compared to vehicle
treated cells. Additionally, three-color confocal immuno-
fluorescence imaging was conducted to visually confirm
the increased accumulation of acetylated histones H3
(Figure 1C) and H4 (Figure 1D) in the panobinostat-
treated cells.
Panobinostat cytotoxicity in TNBC cell lines
To determine the effect of panobinostat on cell prolif-
eration and survival in vitro, three ER-positive and
four TNBC cell lines were treated with increasing
doses (50, 100, 200 nM) of the drug for 24 hours.
Panobinostat induced a significant dose-dependent
decrease in proliferation in all four tested TNBC cell
lines, as assayed by MTT metabolism (Figure 2A). At
200 nM, all TNBC cells had a greater than 40% reduc-
tion in proliferation compared to vehicle treated cells
(P < 0.001). In contrast, the growth of ER-positive cell
lines (MCF-7, ZR-75-1, and MDA-MB-361) was not
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Figure 2 Panobinostat decreases TNBC cell proliferation and viability. Cells from four TNBC cell lines (MDA-MB-157, MDA-MB-231, MDA-MB-
468, BT549) and three ER-positive cell lines (MCF-7, MDA-MB-361, ZR-75) were treated with panobinostat (50, 100, 200 nM) or vehicle (DMSO) for
24 hours and assayed by (A) MTT proliferation and (B) trypan blue exclusion assays. Data are represented as percent control (mean ± SEM) of
three independent experiments, (**, P < 0.01; ***, P < 0.001). DMSO, dimethyl sulfoxide; ER, estrogen receptor; MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide; SEM, standard error of the mean; TNBC, triple-negative breast cancer.
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confirm the accuracy of the MTT assay, trypan blue
assays were also conducted as a measure of membrane
integrity (Figure 2B). Again, cell viability was signifi-
cantly decreased in the TNBC cell lines at all doses
compared to vehicle controls, with a greater than 25%
decrease in cell viability observed at 200 nM in all the
TNBC cell lines (P < 0.001). As with the MTT assay,
panobinostat treatment did not affect ER-positive cell
viability as measured by trypan blue.
The effects of panobinostat on cell cycle progression
were analyzed by propidium iodide flow cytometry at 24
and 72 hours. Panobinostat (100 nM) induced G2/M
cell cycle arrest, as evidenced by accumulation of cells
in G2/M, with a concurrent decrease in S phase peaks
in all four tested TNBC cell lines (Table 1). Treatment
also induced a time-dependent increase in sub-G/debris
fraction in all four TNBC cell lines (data not shown).
Panobinostat-induced apoptosis, as measured by DNA
fragmentation, was assessed at 24 hours in the TNBC
cell lines. A clear induction of apoptosis was apparent at
100 nM and 200 nM concentrations in three of the four
tested TNBC cell lines (P < 0.001), with a mean increase
of 304 ± 0.78% at 200 nM (Figure 3A). Enrichment was
not significant in the MDA-MB-468 cell line at this
time point. Visual evidence of panobinostat-induced
apoptosis (arrows) is presented in the panel of confocal
immunofluorescence images shown in Figures 3B.
Panobinostat targets tumor growth in vivo
To determine if the anti-cancer effects of panobinostat
observed in vitro translated to decreased tumorigenesis
in vivo, immunocompromised female mice were ortho-
topically inoculated with MDA-MB-231 (Figure 4A) or
BT-549 (Figure 4B) cells (5 × 106 cells/site, bilaterally)
and treated with panobinostat or vehicle control. Treat-
ment with panobinostat (10 mg/kg/day, five days/week)
resulted in significant decreases in tumor volume with
three- to four-fold (BT549 and MDA-MB-231, respec-
tively) inhibition of tumor volumes compared to con-
trols by day 41 (28 days post treatment, P < 0.001).
There was no overt toxicity, as measured by weight loss,
noted at this dose and treatment schedule.
Panobinostat regulates breast cancer genes and estrogen
signaling pathways
To reveal possible molecular mechanisms and signaling
pathways involved in TNBC cell response to panobino-
stat, MDA-MB-231 cells were treated for 24 hours and
analyzed with the Human Breast Cancer and Estrogen
Receptor Signaling RT2 Profiler™ PCR Array (SABios-
ciences). As shown in Additional file 1, thirty-five of the
eighty-four representative genes were significantly
altered at least two-fold (P < 0.05). Specifically, expres-
sion of twenty-four genes was up-regulated while
expression of eleven genes was suppressed. Of particular
interest was the 31-fold increase in the documented
epithelial cell marker/tumor suppressor, CDH1 [35].
Also noted were decreases in the proliferation marker
MKI67 and upregulation of the tight-junction protein,
claudin-7.
To further investigate whether the panobinostat-
induced changes discussed above were specific to the
basal-B subtype, MDA-MB-468 (basal-A) and MCF-7
(luminal) cell lines were also tested by Human Breast
Cancer and Estrogen Receptor Signaling RT2 Profiler™
PCR Array following 24 hours of panobinostat treat-
ment. The representative heat map illustrates the
changes in gene expression of all three cell lines fol-
lowing panobinostat treatment as compared to MDA-
MB-231 vehicle treated cells (Figure 5). Additional file
2 shows the twenty-four significantly altered genes in
the MDA-MB-468 cells following panobinostat treat-
ment (P < 0.05), with nineteen genes up-regulated and
five genes down-regulated. Of the up-regulated genes,
many are known to be involved in the promotion of
cell proliferation, survival, and tumor progression
(CCNA1, CCNE1, FOSL1, ITGB4, PAPPA, RAC2, SER-
PINB5), while only three tumor suppressive genes
(CDKN1A, SPRR1B, THBS1) were increased by panobi-
nostat in the MDA-MB-468 cell system. Additional file
3 shows the thirty-four genes significantly altered by
panobinostat in MCF-7 cells (P < 0.05). Of these
altered genes, twenty-four were up-regulated while ten
genes were down-regulated. Again, many of the up-
regulated genes have known roles in cell proliferation,
Table 1 Effect of 100 nM panobinostat on cell cycle
percentage of TNBC cells.
Panobinostat G0/G1 S G2/M
MDA-MB-157 - 24 h 61.72 21.68 16.59
+ 24 h 64.3 10.83 24.87
- 72 h 52.21 25.53 22.26
+ 72 h 54.14 9.48 36.37
MDA-MB-231 - 24 h 86.74 6.03 7.23
+ 24 h 33.04 0.5 66.46
- 72 h 57.05 24.7 18.25
+ 72 h 37.75 2.33 59.92
MDA-MB-468 - 24 h 54.07 30.29 15.64
+ 24 h 51.55 17.01 31.44
- 72 h 53.45 34.81 11.74
+ 72 h 52.67 16.78 30.55
BT-549 - 24 h 37.66 26.57 35.77
+ 24 h 39.76 8.61 51.63
- 72 h 36.42 27.08 36.49
+ 72 h 42.93 3.95 53.13
Data (percent gated cells) representative of two independent experiments.
TNBC, triple-negative breast cancer.
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survival, and tumorigenesis (CCNA1, FGF1, ITGA6,
KLF5, SERPINE1, SLC7A5) in the MCF-7 cells. Addi-
tionally, the well known metastasis suppressor NME1
was decreased by panobinostat in these cells. Overall,
these array data reveal a profile consistent with a less
aggressive, and more favorable, prognostic profile for
MDA-MB-231 cells treated with LHB589, while the
less biologically sensitive MDA-MB-468 and MCF-7
cell lines display a less clear cut picture for
panobinostat-induced gene expression in cells of the
basal-A and luminal subtypes.
Panobinostat induces changes in morphology and CDH-1
expression of MDA-MB-231 cells consistent with reversal
of EMT
To assess potential panobinostat-induced changes in
morphology and cytoskeletal protein expression in
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 *** 
Figure 3 Panobinostat induces apoptosis in TNBC cells. (A) TNBC cells treated with panobinostat (100, 200 nM) or vehicle (DMSO) for 24
hours were assayed by DNA fragmentation (Cell Death ELISA) assay to assess changes in apoptosis. Data are presented as enrichment (mean ±
SEM) versus control of two independent experiments (***, P < 0.001). (B) Representative confocal images show the presence of apoptotic bodies
(arrows) in panobinostat treated MDA-MB-157, MDA-MB-231, and BT-549 cells at 18 hours. Cells stained red (rhodamine phalloidin) for actin
filaments, green (Alexa Fluor® 488) for acetyl-histone H3 (Lys9), and blue for DAPI nuclear stain. Original magnification is 400× with scale bars at
20 microns. DAPI, 4’,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; SEM, standard error of the mean; TNBC, triple-negative breast cancer.
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Figure 4 Effect of panobinostat on tumor growth in MDA-MB-231 and BT549 xenograft models. Female, CB-17/SCID mice (n = 5/group)
were injected with (A) MDA-MB-231-tRFP or (B) BT-549-tRFP cells (5 × 106 cells/injection) bilaterally into the inguinal mammary fat pad. On day
14, mice were treated intraperitoneally (i.p.) with panobinostat (10 mg/kg) or vehicle (1:20 DMSO in normal saline) five days/week for 28 days.
Data points represent average tumor volume ± SEM, (***, P < 0.001). DMSO, dimethyl sulfoxide; SEM, standard error of the mean; tRFP, turbo red
fluorescent protein.
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with panobinostat (100 nM) for 24 hours and analyzed.
Figure 6A shows a significant increase of CDH1-positive
cells in panobinostat treated cells compared to control
(48.5 ± 2.3% to 9.70 ± 0.569%, respectively; P < 0.001).
In confirmation, cells were also assayed by ELISA,
which showed a 1.6-fold increase in CDH1 protein
levels over controls (Figure 6B, P < 0.001). These results
are consistent with our qPCR array finding of a 31-fold
up-regulation of CDH1 expression in MDA-MB-231
cells (Additional file 1). MDA-MB-231 cells also exhib-
ited partial reversal of the mesenchymal phenotype, as
evidenced by a shift from spindle shaped cells with visi-
ble actin stress fibers to predominantly cuboidal/spheri-
cal forms with cortical actin patterns [36-38], following
24-hour treatment with panobinostat (Figure 6C-E). To
determine if the in vitro up-regulation of CDH1 also
occurred in vivo, MDA-MB-231 primary tumor sections
were stained for CDH1. As can be seen in Figure 7,
there is increased CDH1 staining along the periphery of
the panobinostat treated tumor.
Discussion
In recent years, an increasing number of HDACis have
been identified, developed and advanced to clinical trials
[39,40]. Panobinostat has shown potent activity at low
nanomolar concentrations across a wide range of hema-
tologic malignancies and solid tumors in preclinical stu-
dies [20-22,41]. Others have demonstrated that HDACi
treatment can suppress oncogenes and induce re-expres-
sion of previously silenced tumor suppressors and recep-
tors such as the ER [24,42-44]. In addition to its single
agent effects, recent studies have demonstrated a role for
panobinostat in resensitizing cancer cells to other agents
including chemotherapy [45], radiation [46], autophagy
inhibitors [47] and endocrine therapies including tamoxi-
fen [48] and letrozole [49]. In consideration of the pro-
mising results reported by others, we endeavored to
determine whether panobinostat would be effective
against a panel of breast cancer cell lines that display
common characteristics of the triple-negative subtype.
In this study, we utilized MDA-MB-157, MDA-MB-
231, MDA-MB-468, and BT549 cell lines as models of
TNBC growth and progression. In confirmation of other
preclinical research [20,24,42,44,50,51], we found that
panobinostat induced hyperacetylation of histones H3
and H4, decreased proliferation and survival, and
induced apoptosis and G2/M cell cycle arrest. The
MDA-MB-231 and BT549 lines were chosen as models
for our in vivo xenograft studies using CB-17/SCID
mice. Treatment with panobinostat decreased MDA-
MB-231 and BT549 tumor significantly with minimal
animal toxicity, providing preclinical data on the effec-
tiveness of panobinostat on TNBC tumorigenesis at a
low and well tolerated dose.
Figure 5 Heat map of panobinostat -induced gene expression
changes in MDA-MB-231, MDA-MB-468, and MCF-7 cells. MDA-
MB-231, MDA-MB-468, or MCF-7 cells were treated for 24 hours with
panobinostat (100 nM) or vehicle (DMSO) and then assayed via the
Human Breast Cancer and Estrogen Receptor Signaling RT2
Profiler™ PCR Array. Red signifies up-regulation and green signifies
down-regulation by panobinostat compared to MDA-MB-231
vehicle treated controls. Data are representative of three
independent experiments. Genes regulated at least 2-fold are also
summarized in Additional file 1 (MDA-MB-231), 2 (MDA-MB-468) and
3 (MCF-7). DMSO, dimethyl sulfoxide.
Tate et al. Breast Cancer Research 2012, 14:R79
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Figure 6 Panobinostat up-regulates CDH1 expression and initiates EMT reversal in MDA-MB-231 Cells. MDA-MB-231 cells were plated
overnight and treated with panobinostat (100 nM) or vehicle (DMSO) for 24 hours. The expression of CDH1 was examined by (A) flow
cytometry and (B) ELISA. Data are represented as mean ± SEM of two independent experiments, (***, P < 0.001). (C-E) MDA-MB-231 morphology
changes were assessed in vehicle- and panobinostat- (100 n M) treated cells with three-color fluorescence staining on a BD Pathway 855
Bioimager. (C) Control and (D-E) Panobinostat treated cells were stained red (rhodamine phalloidin) for actin filaments, green (Alexa Fluor® 488)
for acetyl-histone H3 (Lys9), and blue (DAPI) nuclear counter stain. Partial reversal of EMT in treated cells is indicated by the presence of
cuboidal/spherical cells (arrows). (E) Two-fold magnification of field with normal untransformed mesenchymal cell and transformed spherical
cells. Original magnification is 400× with scale bars at 20 microns. DAPI, 4’,6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; ELISA, enzyme-
linked immunosorbent assay; EMT, epithelial-to-mesenchymal transition; SEM, standard error of the mean.
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The panobinostat-induced effects on cell prolifera-
tion and survival appear to be TNBC cell specific as
the ER-positive cell lines tested were unaffected at all
doses tested (up to 200 nM), contrary to previously
published work which reported panobinostat signifi-
cantly inhibited cell survival and induced cell death in
ER-positive and ER-negative breast cancer cell lines
though at a different time point [44,47]. We propose
that the more aggressive, highly proliferative nature
and invasive phenotype of TNBC cells render them
particularly susceptible to the effects of panobinostat.
Of the four TNBC cell lines tested, the MDA-MB-468
cells were the most resistant to hyper-acetylation and
DNA degradation by the drug. This is interesting as
this cell line is the most phenotypically different (sphe-
rical morphology) and least invasive of the four tested
cell lines. The MDA-MB-157, MDA-MB-231, and
BT549 lines have been classified as basal-B [52], with
the MDA-MB-231 and BT-549 cell lines specifically
classified as mesenchymal (stellate), claudin-low, and
highly invasive [53-56]. The MDA-MB-157 cells are
classified as mesenchymal, claudin-low, and moderately
invasive [52]. Clinically, the majority of claudin-low
tumors are of the triple-negative subtype and are asso-
ciated with poor overall prognoses [53]. However,
MDA-MB-468 cells have been characterized under the
basal-A subtype, as they possess both basal (triple-
negative) and luminal (spherical morphology) charac-
teristics and are only minimally invasive [52]. Addi-
tionally, super array data comparing panobinostat-
induced gene expression changes between panobino-
stat-sensitive (MDA-MB-231, basal-B) and panobino-
stat-insensitive (MDA-MB-468, basal-A; MCF-7,
luminal) cells revealed several changes specific to the
basal-B subtype [See bolded genes in Additional file 1].
These ten genes include known regulators of cell pro-
liferation (FOSL1, STC2, TGFA, THBS2) and apoptosis











H & E    CDH-1 
Figure 7 Panobinostat increases CDH1 expression in MDA-MB-231 primary tumors. Control and panobinostat treated, formalin-fixed
mammary fat pad sections from MDA-MB-231-tRFP injected CB17-SCID mice were stained for H & E (left column) or anti-human CDH1 (1:30;
right column) followed by Alexa Fluor® 488 secondary antibody. Original magnification was 100× with scale bars at 200 microns. tRFP, turbo red
fluorescent protein; SCID, severe combined immunodeficiency.
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Additionally, many of the genes altered by panobino-
stat specifically in MDA-MB-231 cells have documen-
ted roles in cell invasion and metastasis including
CDH1, CLDN7, FOSL1, PLAU, STC2, and TGFA.
These data support the role of the selective effects of
panobinostat observed on the basal-B cell lines com-
pared to the other subtypes tested.
Interestingly, superarray data identified CDH1 as
being the most induced gene by panobinostat treat-
ment specifically in MDA-MB-231 cells, as these cells
are characterized as mesenchymal, thus lacking signifi-
cant CDH1 expression. The TNBC subtype is exempli-
fied by its highly aggressive and metastatic nature. A
known key step in the process of metastasis is the
epithelial-to-mesenchymal transition (EMT). This
oncogenic EMT is typified by increased invasion and
metastatic dissemination, therapeutic resistance and
loss of expression of tumor suppressors such as CDH1
[57,58]. Studies have demonstrated that EMT and the
resultant loss of CDH1 expression are crucial steps in
tumor progression and correlate with poor clinical out-
comes [59-61]. In confirmation of our in vitro data on
CDH1 up-regulation, we also noted an increase in
CDH1 on the periphery of the primary tumor from
our MDA-MB-231 xenograft model. Decreased CDH1
expression at the tumor periphery has been linked to
increased metastasis-risk and decreased overall patient
survival [62]. Induction of CDH1 expression by
LHB589 at the invasive edge may therefore be indica-
tive of decreased metastatic potential. Panobinostat-
induced re-expression of CDH1, along with other mor-
phological features, indicates the partial reversal of
EMT, a target of enormous potential, particularly in
the TNBC subtype. This suggests panobinostat as a
promising therapeutic option for the more aggressive,
TNBC/basal-like breast cancer subtypes.
Conclusions
Our results illustrate the ability of panobinostat to
hyperacetylate histones, inhibit proliferation and survi-
val, and decrease in vivo tumorigenesis of TNBC cells.
Our in vitro data suggest that this cytotoxicity is par-
tially due to cell cycle arrest and apoptosis. Also noted
in treated cultures was an apparent partial reversal of
the mesenchymal phenotype evidenced by increased
CDH1 protein expression and morphology changes in
MDA-MB-231 cells. This increased CDH1 was con-
firmed with measured upregulation of the CDH1 stain-
ing at the primary tumor periphery in our xenograft
model. Overall, our results affirm the efficacy and
demonstrate a potential therapeutic role of panobinostat
in targeting aggressive triple-negative breast cancer cell
types.
Additional material
Additional file 1: Panobinostat induced expression changes of
breast cancer related genes in MDA-MB-231 cells.
Additional file 2: Panobinostat induced expression changes of
breast cancer related genes in MDA-MB-468 cells.
Additional file 3: Panobinostat induced expression changes of
breast cancer related genes in MCF-7 cells.
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